Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
The Lancet ( IF 98.4 ) Pub Date : 2017-08-01 , DOI: 10.1016/s1470-2045(17)30381-9
William D Tap ₁ , Zsuzsanna Papai ₂ , Brian A Van Tine ₃ , Steven Attia ₄ , Kristen N Ganjoo ₅ , Robin L Jones ₆ , Scott Schuetze ₇ , Damon Reed ₈ , Sant P Chawla ₉ , Richard F Riedel ₁₀ , Anders Krarup-Hansen ₁₁ , Maud Toulmonde ₁₂ , Isabelle Ray-Coquard ₁₃ , Peter Hohenberger ₁₄ , Giovanni Grignani ₁₅ , Lee D Cranmer ₁₆ , Scott Okuno ₁₇ , Mark Agulnik ₁₈ , William Read ₁₉ , Christopher W Ryan ₂₀ , Thierry Alcindor ₂₁ , Xavier F Garcia Del Muro ₂₂ , G Thomas Budd ₂₃ , Hussein Tawbi ₂₄ , Tillman Pearce ₂₅ , Stew Kroll ₂₅ , Denise K Reinke ₂₆ , Patrick Schöffski ₂₇

Affiliation

Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Allami Egeszsegugyi Kozpont (State Health Center), Budapest, Hungary.
Washington University School of Medicine, St Louis, MO, USA.
Mayo Clinic Florida, Jacksonville, FL, USA.
Stanford University Department of Medicine Division of Oncology, Stanford, CA, USA.
University of Washington Cancer Center/Seattle Cancer Care Alliance, Seattle, WA, USA.
University of Michigan Cancer Center, Ann Arbor, MI, USA.
Moffitt Cancer Center, Tampa, FL, USA.
Sarcoma Oncology Center, Santa Monica, CA, USA.
Duke University Medical Center, Durham, NC, USA.
Herlev Hospital, Herlev, Denmark.
Institut Bergonié, Bordeaux, France.
Centre Léon Bérard, Lyon, France.
Universitätsklinikum Mannheim, Mannheim, Germany.
Candiolo Cancer Institute, FPO, IRCCS, Turin, Italy.
University of Arizona Cancer Center, Seattle, WA, USA.
Mayo Clinic, Rochester, MN, USA.
Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Oregon Health and Science University, Portland, OR, USA.
Department of Oncology, McGill University, Montreal, QC, Canada.
ICO Hospital Duran i Reynals, Barcelona, Spain.
Cleveland Clinic Foundation, Cleveland, OH, USA.
University of Pittsburgh Medical Center, Houston, TX, USA.
Threshold Pharmaceuticals, South San Francisco, CA, USA.
Sarcoma Alliance for Research through Collaboration, Ann Arbor, MI, USA.
UZ Leuven, Campus Gasthuisberg, Leuven, Belgium.

Evofosfamide is a hypoxia-activated prodrug of bromo-isophosphoramide mustard. We aimed to assess the benefit of adding evofosfamide to doxorubicin as first-line therapy for advanced soft-tissue sarcomas.

中文翻译：

阿霉素联合依磷酰胺与单用阿霉素治疗局部晚期、不可切除或转移性软组织肉瘤 (TH CR-406/SARC021)：一项国际、多中心、开放标签、随机 3 期试验。

Evofosfamide 是一种缺氧激活的溴异磷酰胺芥末的前药。我们的目的是评估在阿霉素中添加依磷酰胺作为晚期软组织肉瘤一线治疗的益处。

更新日期：2017-08-10

点击分享查看原文

点击收藏

阅读更多本刊最新论文